Biogen : FDA Approves First Oral Treatment For Postpartum Depression
The U.S. Food and Drug Administration approved Zurzuvae (zuranolone) 50 mg for adults with postpartum depression, Sage Therapeutics Inc. (SAGE) and Biogen Inc. (BIIB) said in a statement. Zurzuvae is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with postpartum depression. Until now, treatment for postpartum depression was only available […]
Read more